ZTS · Healthcare
What a holder would want to know before buying ZTS: where the price sits in its own history, how far it has fallen before and whether it recovered, and what the business behind it earns. All of it is arithmetic over free market data — no opinions, no recommendations.
Today’s price is 8% above the lowest point of the past year and 49% below the highest.
Over the past year it was cheaper than today on 15% of days and more expensive on 85%. Over the last 10 years: cheaper on 17% of days.
23% below its average price of the last 200 trading days.
Fell 20% or more twice in 10 years. The deepest fall was 72%; the longest took 5 months to get back to its peak. 1 of 2 have recovered so far.
It is in one now: 70% below the Dec 2021 peak.
Zoetis Inc. · Healthcare · Drug Manufacturers - Specialty & Generic · a large company worth $30.91B
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the…
revenue profit
Sales of $9.47B in 2025, with $2.67B of profit. Sales grew in 3 of the last 3 years.
Keeps about 28 cents of every dollar of sales as profit.
Would need about 4.6 years of free cash flow to repay all its debt.
You pay $12 for every $1 of last year’s profit, and $11 for every $1 of profit expected next year.
A high number means buyers expect growth; a low one means they expect little, or fear trouble. Large US companies have averaged roughly 15–20 over the decades.
Pays 2.90% a year in dividends at today’s price · next ex-dividend Jul 20.
17 analysts: 8 say buy, 9 hold, 0 sell. Their average 12-month target is $96.00 (range $80.00–$155.00).
Insiders made 3 purchases and 0 sales in the last 6 months.
Free data from Yahoo Finance, refreshed daily. This is evidence about the business and its price history, not a recommendation.
Poshkan is paper trading: real prices, virtual money. Buy ZTS with $10,000 that isn’t real, set a stop before you enter, and find out what your idea would actually have done.
Data from Yahoo Finance, refreshed hourly. Nothing here is financial advice. Poshkan is a paper-trading simulator — all money, trades and returns are virtual.